Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03907527 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Refractory Fallopian Tube Carcinoma
Refractory Ovarian Carcinoma
Refractory Primary Peritoneal Carcinoma
Stage III Fallopian Tube Cancer AJCC V8
Stage III Ovarian Cancer AJCC V8
Stage III Primary Peritoneal Cancer AJCC V8
Stage IIIA Fallopian Tube Cancer AJCC V8
Stage IIIA Ovarian Cancer AJCC V8
Stage IIIA Primary Peritoneal Cancer AJCC V8
Stage IIIA1 Fallopian Tube Cancer AJCC V8
Stage IIIA1 Ovarian Cancer AJCC V8
Stage IIIA2 Fallopian Tube Cancer AJCC V8
Stage IIIA2 Ovarian Cancer AJCC V8
Stage IIIB Fallopian Tube Cancer AJCC V8
Stage IIIB Ovarian Cancer AJCC V8
Stage IIIB Primary Peritoneal Cancer AJCC V8
Stage IIIC Fallopian Tube Cancer AJCC V8
Stage IIIC Ovarian Cancer AJCC V8
Stage IIIC Primary Peritoneal Cancer AJCC V8
Stage IV Fallopian Tube Cancer AJCC V8
Stage IV Ovarian Cancer AJCC V8
Stage IV Primary Peritoneal Cancer AJCC V8
Stage IVA Fallopian Tube Cancer AJCC V8
Stage IVA Ovarian Cancer AJCC V8
Stage IVA Primary Peritoneal Cancer AJCC V8
Stage IVB Fallopian Tube Cancer AJCC V8
Stage IVB Ovarian Cancer AJCC V8
Stage IVB Primary Peritoneal Cancer AJCC V8

Interventions

BIOLOGICAL: PRGN-3005 UltraCAR-T cells
BIOLOGICAL: PRGN-3005 UltraCAR-T cells

Sponsor

Precigen, Inc